These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 35981469)

  • 1. Prevalence and associations of classic psychedelic-related seizures in a population-based sample.
    Simonsson O; Goldberg SB; Chambers R; Osika W; Long DM; Hendricks PS
    Drug Alcohol Depend; 2022 Oct; 239():109586. PubMed ID: 35981469
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.
    Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB
    J Affect Disord; 2023 Apr; 326():105-110. PubMed ID: 36720405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports.
    Nayak SM; Gukasyan N; Barrett FS; Erowid E; Erowid F; Griffiths RR
    Pharmacopsychiatry; 2021 Sep; 54(5):240-245. PubMed ID: 34348413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Classic Psychedelics and Human-Animal Relations.
    Pöllänen E; Osika W; Stenfors CUD; Simonsson O
    Int J Environ Res Public Health; 2022 Jul; 19(13):. PubMed ID: 35805769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between lifetime classic psychedelic use and markers of physical health.
    Simonsson O; Sexton JD; Hendricks PS
    J Psychopharmacol; 2021 Apr; 35(4):447-452. PubMed ID: 33719688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Linkages between Psychedelics and Meditation in a Population-Based Sample in the United States.
    Simonsson O; Goldberg SB
    J Psychoactive Drugs; 2023; 55(1):11-18. PubMed ID: 35000559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between lifetime classic psychedelic use and cardiometabolic diseases.
    Simonsson O; Osika W; Carhart-Harris R; Hendricks PS
    Sci Rep; 2021 Jul; 11(1):14427. PubMed ID: 34257396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence and epidemiological associates of novel psychedelic use in the United States adult population.
    Sexton JD; Crawford MS; Sweat NW; Varley A; Green EE; Hendricks PS
    J Psychopharmacol; 2019 Sep; 33(9):1058-1067. PubMed ID: 30816808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classic psychedelics, health behavior, and physical health.
    Simonsson O; Hendricks PS; Chambers R; Osika W; Goldberg SB
    Ther Adv Psychopharmacol; 2022; 12():20451253221135363. PubMed ID: 36465958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is psychedelic use associated with cancer?: Interrogating a half-century-old claim using contemporary population-level data.
    Barnett BS; Ziegler K; Doblin R; Carlo AD
    J Psychopharmacol; 2022 Oct; 36(10):1118-1128. PubMed ID: 35971893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between classic psychedelics and opioid use disorder in a nationally-representative U.S. adult sample.
    Jones G; Ricard JA; Lipson J; Nock MK
    Sci Rep; 2022 Apr; 12(1):4099. PubMed ID: 35393455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between Lifetime Classic Psychedelic Use and Sick Leave in a Population-Based Sample.
    Mellner C; Dahlen M; Simonsson O
    Int J Environ Res Public Health; 2022 Sep; 19(18):. PubMed ID: 36141631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relationships of classic psychedelic use with criminal behavior in the United States adult population.
    Hendricks PS; Crawford MS; Cropsey KL; Copes H; Sweat NW; Walsh Z; Pavela G
    J Psychopharmacol; 2018 Jan; 32(1):37-48. PubMed ID: 29039233
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Safety and Efficacy of Psychedelic-Assisted Therapies for Older Adults: Knowns and Unknowns.
    Johnston CB; Mangini M; Grob C; Anderson B
    Am J Geriatr Psychiatry; 2023 Jan; 31(1):44-53. PubMed ID: 36184377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Race and ethnicity moderate the associations between lifetime psychedelic use (MDMA and psilocybin) and psychological distress and suicidality.
    Jones GM; Nock MK
    Sci Rep; 2022 Oct; 12(1):16976. PubMed ID: 36216840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psychedelic-Assisted Group Therapy: A Systematic Review.
    Trope A; Anderson BT; Hooker AR; Glick G; Stauffer C; Woolley JD
    J Psychoactive Drugs; 2019; 51(2):174-188. PubMed ID: 30950777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychedelic philanthropy: The nonprofit sector and Timothy Leary's 1960s psychedelic movement.
    Elcock C
    J Hist Behav Sci; 2022 Jan; 58(1):85-104. PubMed ID: 33524159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.